Zoetis Inc. (ZTS)
Zoetis Inc. (ZTS) from its SEC filings: 2025 revenue $9.5 billion (+2% vs the year before), net margin 28%, free cash flow $2.3 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $9.5 billion |
| Revenue growth | +2% |
| Net income | $2.7 billion |
| Net margin | 28.2% |
| Free cash flow | $2.3 billion |
| Diluted EPS | $6.02 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -0% |
| Cash | $1.5 billion |
| Long-term debt | $9.0 billion |
| Share count, 1 year | -7% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.